This week, Psychedelic Alpha’s Noah Smith takes a look ahead to one of the most eagerly anticipated data readouts of the year, Perception Neuroscience’s (part of the atai platform) Phase 2a trial of PCN-101 (R-ketamine or arketamine) for treatment-resistant depression (TRD). Here, Noah explores the history of ketamine and its two enantiomers (S-Ketamine, marketed as Spravato, and R-Ketamine)…


Previous articleSurprising Results: Psilocybin Trial for Depression Alleviates Chronic Pain
Next articlePsychedelics Weekly – Oregon Measure 109: Approaching the Proposed Final Rules